Zahid Kocak, M. 2021. Comment on ‘Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab’. Acta Oncologica. 60, 4 (Apr. 2021), 564–565. DOI:https://doi.org/10.1080/0284186X.2021.1889028.